Latest Insider Transactions at Kal Vista Pharmaceuticals, Inc. (KALV)
This section provides a real-time view of insider transactions for Kal Vista Pharmaceuticals, Inc. (KALV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of KalVista Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of KalVista Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,077
-7.9%
|
$72,693
$9.26 P/Share
|
|
Nov 18
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
7,192
-7.4%
|
$64,728
$9.26 P/Share
|
|
Nov 18
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
14,400
-5.12%
|
$129,600
$9.26 P/Share
|
|
Nov 17
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,531
+15.34%
|
-
|
|
Nov 17
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,496
+10.58%
|
-
|
|
Nov 17
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,198
+9.7%
|
-
|
|
Sep 09
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,352
-2.85%
|
$88,224
$12.19 P/Share
|
|
Sep 06
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+5.71%
|
-
|
|
Aug 23
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,135
-2.49%
|
$25,620
$12.4 P/Share
|
|
Aug 23
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,916
-2.19%
|
$22,992
$12.4 P/Share
|
|
Aug 22
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+5.5%
|
-
|
|
Aug 22
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+3.44%
|
-
|
|
Aug 19
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
7,102
-7.76%
|
$85,224
$12.01 P/Share
|
|
Aug 19
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
14,215
-5.54%
|
$170,580
$12.01 P/Share
|
|
Aug 19
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
7,973
-8.97%
|
$95,676
$12.01 P/Share
|
|
Aug 17
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,495
+11.15%
|
-
|
|
Aug 17
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,195
+10.52%
|
-
|
|
Aug 17
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,528
+17.25%
|
-
|
|
Jun 07
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,465
-3.22%
|
$82,115
$11.53 P/Share
|
|
Jun 06
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+6.31%
|
-
|
|
May 20
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
11,610
-12.66%
|
$127,710
$11.76 P/Share
|
|
May 20
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
21,959
-9.21%
|
$241,549
$11.76 P/Share
|
|
May 20
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
13,175
-15.78%
|
$144,925
$11.76 P/Share
|
|
May 20
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
8,088
-9.99%
|
$88,968
$11.76 P/Share
|
|
May 17
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,789
+17.01%
|
-
|
|
May 17
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
51,031
+17.63%
|
-
|
|
May 17
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,614
+26.83%
|
-
|
|
May 17
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,789
+18.84%
|
-
|
|
Feb 20
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
28,288
-11.21%
|
$396,032
$14.29 P/Share
|
|
Feb 20
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
22,802
-10.85%
|
$319,228
$14.11 P/Share
|
|
Feb 20
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
12,053
-14.19%
|
$168,742
$14.11 P/Share
|
|
Feb 20
2024
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
24,888
-10.54%
|
$348,432
$14.11 P/Share
|
|
Feb 20
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
14,295
-21.28%
|
$200,130
$14.12 P/Share
|
|
Feb 17
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,788
+17.2%
|
-
|
|
Feb 17
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
51,029
+19.54%
|
-
|
|
Feb 17
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,788
+18.11%
|
-
|
|
Feb 17
2024
|
Thomas Andrew Crockett CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
54,415
+18.73%
|
-
|
|
Feb 17
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,613
+31.3%
|
-
|
|
Feb 14
2024
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
58,356
-24.31%
|
$875,340
$15.01 P/Share
|
|
Feb 14
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
40,855
-20.43%
|
$612,825
$15.01 P/Share
|
|
Feb 14
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
39,886
-37.61%
|
$598,290
$15.01 P/Share
|
|
Feb 14
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
28,171
-28.22%
|
$422,565
$15.01 P/Share
|
|
Feb 11
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+37.54%
|
-
|
|
Feb 11
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+30.44%
|
-
|
|
Feb 11
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+36.13%
|
-
|
|
Feb 11
2024
|
Thomas Andrew Crockett CEO |
BUY
Grant, award, or other acquisition
|
Direct |
122,500
+33.79%
|
-
|
|
Feb 08
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
29,747
+0.61%
|
$416,458
$14.7 P/Share
|
|
Feb 07
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
51,827
+1.07%
|
$725,578
$14.56 P/Share
|
|
Feb 06
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
4,474
+0.09%
|
$62,636
$14.74 P/Share
|
|
Feb 01
2024
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
10,000
-3.94%
|
$160,000
$16.5 P/Share
|